product summary
Loading...
company name :
OriGene
product type :
other
product name :
CDC42SE2 Human qPCR Primer Pair (NM_001038702)
catalog :
HP203228
quantity :
200 reactions
price :
142 USD
more info or order :
product information
SKU :
HP203228
Category :
Gene Expression
Sub-Category :
qPCR Primer Pairs
Name :
CDC42SE2 Human qPCR Primer Pair (NM_001038702)
Description :
qSTAR qPCR primer pairs against Homo sapiens gene CDC42SE2
Size :
200 reactions
Price US :
142 USD
Delivery Time US :
5 Days
Symbol :
CDC42SE2
Uniprot ID :
Q9NRR3
Accn :
NM_001038702 , NM_020240 , NM_020240.1 , NM_020240.2 , NM_001038702.1 , BC096703 , BC023555 , BC050430 , BC058909 , BC096738 , BC098349 , BI460220 , BI522591 , NM_020240.3 , NM_001038702.2
more info or order :
company information

OriGene
9620 Medical Center Dr., Suite 200
Rockville, MD 20850
Rockville, MD 20850
custsupport@origene.com
https://www.origene.com1-888-267-4436
headquarters: USA
OriGene Technologies, Inc. is a gene centric life sciences company dedicated to support biomedical scientists in gene functions and drug discovery. OriGene’s novel product line includes the world’s largest collections of cDNA clones (TrueClone and TrueORF), shRNA (HuSH-29), purified human recombinant proteins, high quality TrueMAB™ monoclonal antibodies to human proteins, 100,000 highly validated human tissues, and qPCR arrays. OriGene also provides a broad range of antibody validation products including genome-wide tagged antigen standards and extensive IHC slides derived from our tissue collection. OriGene is a Luminex Certified Partner™ and offers multiplexed immunoassays and multiplexed assays for a broad range of biomarkers.
related products
browse more products
- C17orf47 Human qPCR Primer Pair (NM_001038704) | HP203229
- GPR149 Human qPCR Primer Pair (NM_001038705) | HP203230
- FER1L6-AS1 Human qPCR Primer Pair (NM_001038706) | HP203231
- epithelial Sodium Channel gamma (SCNN1G) Human qPCR Primer Pair (NM_001039)
- LRTM2 Human qPCR Primer Pair (NM_001039029) | HP203234
questions and comments